Loading...
XASX
GSS
Market cap13mUSD
Oct 09, Last price  
0.08AUD
1D
1.20%
1Q
31.25%
Jan 2017
-81.33%
IPO
-80.91%
Name

Genetic Signatures Ltd

Chart & performance

D1W1MN
XASX:GSS chart
P/E
—
P/S
1.32
EPS
—
Div yield, %
—
Shrs. gr., 5y
8.78%
Rev. gr., 5y
-12.57%
Revenues
14m
-9.10%
256,9771,292,5291,043,2693,265,7874,061,5464,993,7557,024,00011,263,00028,284,00035,421,00016,939,0009,766,00015,900,00014,453,000
Net income
-14m
L-30.33%
-2,014,401-1,728,487-2,659,120-3,026,598-2,670,622-3,253,809-3,492,000-2,086,0001,756,0003,063,000-14,052,000-17,862,000-20,104,000-14,006,000
CFO
-8m
L-36.77%
-1,186,909-1,354,737-2,795,142-2,572,311-2,571,868-3,693,561-2,269,000-9,494,0004,195,0009,806,000-12,451,000-10,120,000-12,289,000-7,770,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.

Key people

Non-Executive Chairman of the Board · since 2024
Chief Executive Officer · since 2026
Allison Rossiter
Chief Executive Officer · since 2024
Michael Aicher
Executive Director - US Operations · since 2014
Karl Pechmann
Chief Financial Officer, Joint Company Secretary · since 2025
Michael Sapountzis
Joint Company Secretary · since 2025
Jenny Harry
Director · since 2024
Neil Gunn
Non-Executive Director · since 2024
IPO date
Mar 31, 2015
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT